Mercaptopurina Silver

Mercaptopurine, the active ingredient in Mercaptopurina Silver, is a purine analog antimetabolite presented as an oral tablet for oral use. It is employed in the treatment of acute lymphoblastic leukemia, chronic myeloid leukemia, and inflammatory bowel disease such as Crohn’s disease and ulcerative colitis in eligible patients.

GNH USA supplies Mercaptopurina Silver as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies, and clinics, ensuring timely delivery and regulatory compliance across multiple continents for.

Mercaptopurine is used in hematologic malignancies and inflammatory bowel disease to inhibit abnormal cell proliferation.

- Acute lymphoblastic leukemia: induces remission by targeting rapidly dividing lymphoblasts. - Chronic myeloid leukemia: contributes to disease control when combined with other agents. - Crohn’s disease: reduces intestinal inflammation and maintains long‑term remission. - Ulcerative colitis: helps sustain remission and decrease steroid dependence. - Graft‑versus‑host disease prophylaxis: provides immunosuppression to prevent donor‑derived immune reactions.

Mercaptopurine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may affect hydration. - Fatigue: generalized tiredness. - Rash: skin irritation or erythema.

Serious or Rare Side Effects: - Bone marrow suppression: severe neutropenia or anemia. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe infection: opportunistic infections due to immunosuppression. - Pancreatitis: acute inflammation of the pancreas.

When prescribing Mercaptopurina Silver, clinicians should observe several safety measures.

- Dose adjustment in renal or hepatic impairment: modify dose based on organ function. - Monitor blood counts regularly: check CBC to detect myelosuppression. - Avoid use in pregnancy unless essential: teratogenic risk (Category D). - Use effective contraception: prevent fetal exposure. - Avoid live vaccines: immunosuppression may increase risk. - Store at below 25°C: keep in the original pack, protect from moisture.

Mercaptopurine interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Allopurinol: increased risk of myelosuppression. - Warfarin: enhanced anticoagulant effect. - Azathioprine: additive immunosuppression.

Moderate Interactions (Monitor Closely): - 5‑ASA agents: may increase mercaptopurine toxicity. - Methotrexate: overlapping marrow suppression. - Rifampin: may reduce plasma levels of mercaptopurine.